Skip to main content
. 2019 Apr 3;8(4):308. doi: 10.3390/cells8040308

Figure 2.

Figure 2

Assessment of clinical outcomes of OA patients treated with SVF at 12 and 24 months. (A) Visual analogue scale (VAS) score (B) Western Ontario and McMaster Universities Arthritis Index (WOMAC) index, and (C) Lysholm score of the SVF-treated group compared to the placebo group.